Back to Elevai Labs
(Nasdaq: ELAB)
Company Info
Overview
Management
FAQ
News
Press Releases
Stock Data
SEC Filings
Governance
Contact
Investors
We rely on the capital markets for the growth of our brands.
View Stock Data
Investor Materials
Upcoming Events
Latest Press Releases
View All
May 2, 2024
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
May 1, 2024
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
May 1, 2024
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
Latest Filings
8-K
Current report
10-K
Annual report [Section 13 and 15(d), not S-K Item 405]
8-K
Current report
View All
Track all markets on TradingView
